Sort   by:  
 Page size 
UnknownInteractions between the lipidome and genetic and environmental factors in autism.
Not available
S-EPMC10115648 | biostudies-literature
UnknownOdronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Not available
S-EPMC12003196 | biostudies-literature
UnknownAflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Not available
S-EPMC4422053 | biostudies-literature
UnknownAntiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Not available
S-EPMC5854459 | biostudies-literature
UnknownPlasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Not available
S-EPMC6568257 | biostudies-literature
UnknownExtracorporeal Life Support Organization Registry International Report 2022: 100,000 Survivors.
Not available
S-EPMC10962646 | biostudies-literature
UnknownExploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
Not available
S-EPMC4162127 | biostudies-literature
UnknownRandomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
Not available
S-EPMC2937272 | biostudies-literature
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536 | biostudies-literature
Sort   by:  
 Page size